Clinical Trial Update: A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas [Phase 2]

View source ↗

Summary

Phase 2 pilot study evaluating acalabrutinib in relapsed or refractory central nervous system lymphomas; the trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Central Nervous System Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING